bisphosphonate


Also found in: Dictionary, Wikipedia.

diphosphonate

 [di-fos´fo-nāt]
any of a group of related phosphorus-containing compounds that are structurally similar to pyrophosphate but have enhanced stability to enzymatic and chemical hydrolysis and have affinity for sites of osteoid mineralization. They are used as sodium salts to inhibit bone resorption as well as complexed with technetium Tc 99m for bone imaging. The group includes alendronate, etidronate, and pamidronate. Called also bisphosphonate.

bisphosphonate

(bīs-fos-fō'nāt),
Member of a class of drugs used for treatment of osteoporosis; works by inhibiting osteoclast-mediate resorption of bone.

bisphosphonate

/bis·phos·pho·nate/ (bis-fos´fo-nāt) diphosphonate.

bisphosphonate

(bĭs′fŏs′fə-nāt′)
n.
Any of a class of drugs that decrease bone resorption by inhibiting osteoclasts, used in the treatment of osteoporosis, Paget's disease, bone metastases, and other conditions. Also called diphosphonate.

bisphosphonate

[bis-fos′fo-nāt]
diphosphonate.

bisphosphonate

Any of a family of drugs with two phosphonate (PO3) groups, which inhibit enzymes that break down pyrophosphate. Bisphosphonates include etidronate and clodronate (first-generation agents), and pamidronate disodium (a second-generation bisphosphonate), which inhibits bone resorption at doses that do not affect bone mineralisation. Bisphosphonates are potent inhibitors of bone resorption that bind tightly to the hydroxyapatite crystals, and have therapeutic potential in osteoporosis and in advanced (stage-III) multiple myeloma and Paget’s disease of bone.

Indications
Treat and prevent osteoporosis, osteolysis due to metastatic breast and prostate cancer, multiple myeloma, Paget's disease of bone, fibrous dysplasia, Gaucher's disease, etc.

Adverse effect
Upset stomach, gastritis, oesophageal erosions; long-term effects include femoral fractures and an increased risk of oesophageal cancer.

Agents
Etidronate, clodronate, tiludronate.

Bisphosphonate

A class of drugs used to treat Paget's disease. These drugs bind to the minerals in bone tissue and lessen the amount of bone loss associated with Paget's disease.

bis·phos·pho·nate

(bī-fosfŏ-nāt)
Member of a class of drugs used for treatment of osteoporosis; works by inhibiting osteoclast-mediate resorption of bone. bisphosphonate

bisphosphonate (bisfos´fənōt),

n brand names: Fosamax, Didrone;
drug class: two classes: the N-containing (atendronate) and non-N-containing (Etidronate);
action: used to inhibit bone resorption;
uses: prevention and treatment of osteoporosis, osteitis deformans (“Paget's disease of bone”), bone metastasis (with or without hypercalcemia), multiple myeloma and other conditions that feature bone fragility. Can rarely cause osteonecrosis of the jaw; this may be reason to postpone drug treatment until after dental treatment, as they remain bound to the bone for a prolonged period. Most cases occur in high-dose intravenous types used in cancer patients, but a small proportion happens in patients on oral types. Also called
diphosphonate. See also osteonecrosis, bisphosphonate-associated (BON).
References in periodicals archive ?
The study participants were placed in five groups, based on fracture type and bisphosphonate use.
Just under one-quarter of the women were on bisphosphonate therapy.
When an insufficiency fracture is identified in a patient taking a bisphosphonate, the medication should be discontinued and a consultation with Endocrinology should be arranged.
In January 2016, a task force of the American Society for Bone and Mineral Research released guidelines on the optimal duration of bisphosphonate therapy in patients with osteoporosis.
Regarding this pathway, it is very important to evaluate the patients dental situation and oral hygiene before and during the bisphosphonate therapy to prevent BRONJ.
A An association has been found between bisphosphonates and "atypical" fractures in the femur (thighbone).
These findings are especially important because they show romosozumab provided significant hip bone improvements in a population that remained at high risk of fracture despite bisphosphonate therapy, said Bente Langdahl, Ph.
VI]-alendronate complex was most effective against all three lines and that the Mo-POM and bisphosphonate ligand have a synergistic effect.
Osteoporosis was diagnosed based on low T-score in DEXA, and bisphosphonate therapy was initiated (70 mg alendronate sodium/week).
After the radiographical evaluation, bisphosphonate treatment was stopped and bed rest was advised.
Bhat and colleagues obtained the age-specific incidence of distal radius fractures among women aged 65 and older, as well as the rates of hip fracture following wrist fractures, both for those who did and did not receive the bisphosphonate risendronate.